Headline
The latest stories from AHA Today.
Medicare patients who receive care in a hospital outpatient department are more likely to be poorer and have more severe chronic conditions than Medicare patients treated in an independent physician office, according to a study released by the AHA.
The House of Representatives voted 384-38 to pass a bill that, among other health care provisions, would eliminate the 2% across-the-board cut to all Medicare payments, known as sequestration, until the end of 2021.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices holds an emergency meeting on the Johnson & Johnson (Janssen) COVID-19 vaccine to review reports that six women aged 18-48 experienced a rare but serious condition involving blood clots and low…
A recent article in American Economic Review provides an “outdated and recycled take” on the effect of hospital consolidation on wages, writes AHA General Counsel Melinda Hatton.
The Campaign for Sustainable Rx Pricing launched a grassroots and digital advertising campaign urging policymakers to lower prescription drug prices.
Fourteen organizations, including the AHA, urged the Department of Health and Human Services to extend the Next Generation Accountable Care Organization model through 2022, and create a permanent full-risk ACO option based on it for the future.
Hackensack Meridian Health’s clinical experts have learned a wide variety of important lessons and strategies for managing COVID-19’s toll on mental health, write three of the health system’s leaders.
As National Hospital Week (May 9-15) approaches with the theme Inspiring Hope through Healing, the AHA would like to honor the entire community of hospital and health system team members for all of their work.
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2 by 81% in a phase 3 clinical trial conducted with the National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals…
The Food and Drug Administration and Centers for Disease Control and Prevention jointly recommended a pause in the use of Johnson & Johnson’s COVID-19 vaccine, following six reported cases of rare but severe types of blood clots following the vaccine’s administration.